At a glance
ClinicalIndex Comparison RecordN/ACompleted· 14 enrolled
Drug / intervention
SpaceOAR Hydrogeldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study to Evaluate the Safety and Effectiveness of Radiotherapy for Localized T1-T2 Prostate Cancer in China After Injection of SpaceOAR Hydrogel
In Brief
An observational study evaluating SpaceOAR Hydrogel for Prostate Cancer. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedFeb 2023
Primary CompletionApr 2024
Study CompletionAug 2024
TodayJul 2026
First PostedFeb 21, 2023
Enrollment StartNov 3, 2022
Primary CompletionApr 30, 2024
Study CompletionAug 21, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.4 years ago
Interventions
SpaceOAR Hydrogeldevice
The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum